Gatipotuzumab

DB18861InvestigationalProtein Based Therapies

Gatipotuzumab is under investigation in clinical trial NCT01899599 (Pankomab-gex™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer).

Mechanism
Curator reviewed
Also known as
Immunoglobulin g1, anti-(mucin muc1) (human-mus musculus monoclonal pankomab-gex heavy chain), disulfide with human-mus musculus monoclonal pankomab-gex light chain, dimer

Resolves to

Compound
UNII85V55ZLV2ZCAS1264737-26-9
Targets
P15941MUC1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Gatipotuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In